Genomics (NASDAQ:TXG – Get Free Report) had its price objective reduced by equities researchers at Stifel Nicolaus from ...
Genomics company 10x and Harvard University have agreed to resolve a patent lawsuit against 10x's rival Vizgen four days into ...
Morgan Stanley analyst Tejas Savant maintained a Buy rating on 10x Genomics (TXG – Research Report) today and set a price target of $26.00. The ...
Biotech company 10x Genomics (NASDAQ:TXG) reported Q4 CY2024 results , but sales fell by 10.3% year on year to $165 million.
Genomics reported a Q4 EPS loss of $(0.40), missing estimates, while revenue declined 10% year over year. Analysts lowered price targets amid profitability concerns.
Barclays lowered the firm’s price target on 10x Genomics (TXG) to $15 from $18 and keeps an Overweight rating on the shares.Maximize Your ...
While the spotlight has been on the SEC’s legal battles and XRP’s market movements, savvy investors have been securing their ...
Wall Street Pepe Completes Presale, Forecasting 10x Gains Wall Street Pepe ($WEPE) has wrapped up its presale, with ...